154 related articles for article (PubMed ID: 20492887)
21. Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence.
Strohal R; Chimenti S; Vena GA; Girolomoni G
J Dermatolog Treat; 2013 Jun; 24(3):199-208. PubMed ID: 22812568
[TBL] [Abstract][Full Text] [Related]
22. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
Mössner R; Reich K
Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
[TBL] [Abstract][Full Text] [Related]
23. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
Montesu MA; Addis GM; Satta R; Cottoni F
G Ital Dermatol Venereol; 2011 Aug; 146(4):273-81. PubMed ID: 21785393
[TBL] [Abstract][Full Text] [Related]
24. The treatment of psoriasis with etanercept.
Strober BE
Semin Cutan Med Surg; 2005 Mar; 24(1):28-36. PubMed ID: 15900796
[TBL] [Abstract][Full Text] [Related]
25. Severe hypoglycemia after initiation of anti-tumor necrosis factor therapy with etanercept in a patient with generalized pustular psoriasis and type 2 diabetes mellitus.
Wambier CG; Foss-Freitas MC; Paschoal RS; Tomazini MV; Simão JC; Foss MC; Foss NT
J Am Acad Dermatol; 2009 May; 60(5):883-5. PubMed ID: 19389539
[No Abstract] [Full Text] [Related]
26. Etanercept for psoriasis: two case reports.
Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A
Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
28. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
Mease PJ
Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
[TBL] [Abstract][Full Text] [Related]
29. Clinical markers predictive of primary inefficacy: a "real life" retrospective study in psoriatic patients treated with etanercept.
Giunta A; Babino G; Manetta S; Mazzotta A; Chimenti S; Esposito M
Drug Dev Res; 2014 Nov; 75 Suppl 1():S27-30. PubMed ID: 25381970
[TBL] [Abstract][Full Text] [Related]
30. [Intermittent use of etanercept in psoriasis].
Herrera E; Alcaide AJ
Actas Dermosifiliogr; 2010 May; 101 Suppl 1():18-25. PubMed ID: 20492876
[TBL] [Abstract][Full Text] [Related]
31. Etanercept combined with methotrexate for high-need psoriasis.
Driessen RJ; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
[TBL] [Abstract][Full Text] [Related]
32. Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study.
Di Lernia V; Ricci C; Lallas A; Ficarelli E
J Dermatolog Treat; 2014 Feb; 25(1):73-4. PubMed ID: 23621374
[TBL] [Abstract][Full Text] [Related]
33. Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population.
Abreu C; Magro F; Santos-Antunes J; Pilão A; Rodrigues-Pinto E; Bernardes J; Bernardo A; Magina S; Vilas-Boas F; Lopes S; Macedo G; Sarmento A
J Crohns Colitis; 2013 Nov; 7(10):e486-92. PubMed ID: 23583099
[TBL] [Abstract][Full Text] [Related]
34. Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis.
Esposito M; Mazzotta A; Saraceno R; Schipani C; Chimenti S
Int J Immunopathol Pharmacol; 2009; 22(1):219-25. PubMed ID: 19309569
[TBL] [Abstract][Full Text] [Related]
35. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis.
Langley RG; Strober BE; Gu Y; Rozzo SJ; Okun MM
Br J Dermatol; 2010 Jun; 162(6):1349-58. PubMed ID: 20394634
[TBL] [Abstract][Full Text] [Related]
36. [Pustular psoriasis, palmoplantar psoriasis, erythodermal psoriasis and etanercept].
López-Estebaranz JL; Ruiz-Genao D
Actas Dermosifiliogr; 2010 May; 101 Suppl 1():35-9. PubMed ID: 20492878
[TBL] [Abstract][Full Text] [Related]
37. Etanercept treatment for children and adolescents with plaque psoriasis.
Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A;
N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863
[TBL] [Abstract][Full Text] [Related]
38. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
[TBL] [Abstract][Full Text] [Related]
39. Use of etanercept in the dermatology setting. A review.
Lebwohl MG
Am J Clin Dermatol; 2005; 6(1):49-59. PubMed ID: 15675890
[TBL] [Abstract][Full Text] [Related]
40. [Long-term safety and efficacy of etanercept in the treatment of psoriasis].
Zaragoza V; Pérez A; Sánchez JL; Oliver V; Martínez L; Alegre V
Actas Dermosifiliogr; 2010; 101(1):47-53. PubMed ID: 20109392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
